Navigation Links
Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Date:6/2/2008

ing the clinical safety endpoints. There were no observed clinically relevant adverse events associated with the treatment at all the concentrations (0 to 40 mg of SL017) and light doses (10 to 20 joules/cm(2)) administered. The light treatment, conveniently administered in a dermatology clinic, was well tolerated. The therapeutic potential of SL017 was evidenced by the expected (PDT) effects, such as redness, edema, occasional blisters, stinging and burning. The clinical correlates of dyskeratosis and inflammation were likewise appropriately noted on skin biopsy. Clinical and pathological results correlated very well, and conformed not only to the expected effects of PDT but also to the dosage of the drug and light energy administered. The study suggests that a 2% topical formulation of SL017 and a fluence of 20 joules/cm (2) provide expected PDT outcomes. Importantly, this Phase I study did not identify any safety concerns with respect to the parameters evaluated at the dosages of drug and light employed.

"I am encouraged by the confirmation of the topical PDT effects of SL017 and its potential for future applications in a variety of dermatological conditions including Actinic Keratosis," commented Dr. Gilles Lauzon, former Director, Division of Dermatology, University of Alberta and one of the investigators of the study.

The potential applications of cutaneous PDT also include acne, rosacea, superficial skin cancers, cutaneous T-cell lymphoma, localized scleroderma, warts, leishmaniasis and skin rejuvenation. Quest has already shown the follicular uptake of SL017 in humans; and is currently conducting a 90-patient trial addressing potential hair removal applications with results anticipated by end of this year. The Company is also evaluating the utility of SL017 for the treatment of acne in a preclinical model.

Paramount Biosciences, a global pharmaceutical and healthcare investment firm, has exclusive rights to develop and commercialize SL01
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 BioNorth ... serving and representing the life sciences industry in ... of Directors meeting at The Foundry in Dallas ... the organization brought together a broad spectrum of ... underscored the organization's early successes in partnering with ...
(Date:5/28/2015)... Mass. , May 28, 2015 RXi ... focused on discovering and developing innovative therapeutics, primarily in ... pricing of a public offering of 26 million units ... share for gross proceeds of approximately $10.4 million. Each ... (ii) a 13-month overallotment purchase right to purchase 0.50 ...
(Date:5/28/2015)... 2015  GenVec, Inc. (Nasdaq: GNVC ) today ... Swirsky , will present a company overview at the ... on Thursday, June 4, 2015. The ... be available at the following link:  http://wsw.com/webcast/jeff88/gnvc .  ... To access, visit www.genvec.com , click on "Investors ...
(Date:5/28/2015)... The Fertility Centers of New England is proud ... taken on a new and expanded role as Medical ... leadership, oversight and quality assurance for the practice. , ... team of experienced reproductive endocrinologists,” said Fertility Centers of ... “Her expertise and compassionate, individualized care have helped set ...
Breaking Biology Technology:BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces $10 Million Public Offering of Common Stock and Warrants 3GenVec To Present At The Jefferies Healthcare Conference 2Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... May 14 - Bioniche Pharma, a leading ... launch of Enlon (R) (edrophonium chloride injection, ... sulfate, USP) Injection. (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO )"The ... Bioniche,s continued growth and a commitment to bringing ...
... May 14 Nucletron, a,knowledge-based leader in ... Oncentra(R) Brachy, a comprehensive film- and volume-based ... for brachytherapy.,Oncentra Brachy, the world,s first fully ... planning system that features,state-of-the-art optimization algorithms to ...
... - YM BioSciences Inc. (NYSE Amex: YMI , ... identifies and advances a diverse portfolio of promising cancer-related ... and financial results for the third quarter of fiscal ... days ago we reported critically important data at the ...
Cached Biology Technology:Nucletron Releases Comprehensive Film-and Volume-Based Planning System for Wide Variety of Brachy Solutions 2YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 10YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 11
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/14/2015)... DUBLIN , May 14, 2015 Research and ... addition of the "Fingerprint Sensors Market in Smart ... This report believes that 2014 was a watershed ... to Apple,s introduction of ,Apple Pay,. Apple gave fingerprint ... its mobile payment service. Fingerprint sensors are a must-have ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... most, if not all, autoimmune disorders, such as asthma, inflammatory ... to do thanks to a team of researchers who have ... unnecessary immune reactions. This molecule, pronounced "alpha v beta 6," ... through our bodies, and it may be the key that ...
... available in German . In Zebra Finches, ... offspring rearing. The social partner of a female, however, is ... opportunity arises, females will choose to pair with partners other ... the offspring of different fathers have different qualities. And, as ...
... suggests that rats fed homobrassinolide, found in the mustard plant, ... well as the number and size of muscle fibers. ... mass, and get ripped, a new research report published in The ... want to look to your garden for a little help. That,s ...
Cached Biology News:Scientists discover a 'master key' to unlock new treatments for autoimmune disorders 2Sexy sons thanks to mom 2Lift weights, eat mustard, build muscles? 2
... Columns are designed for the rapid purification of ... agarose gels. The DNA band is excised from ... Embedded within the base of the column are ... agarose and impurities back while allowing DNA to ...
...
... The Synaptic Vesicles Isolation Kit ... preparing an enriched synaptic vesicle fraction. ... hypo-osmotic lysis of the synaptosomes, and ... density gradient. The kit also contains ...
... designed for recovery of DNA from TAE and TBE ... Ultra fast protocol: DNA is ready to use in ... resuspend Bead uniformity prevents shearing of high molecular ... DNA is eluted into sterile water or TE ...
Biology Products: